The notices it replaced
- Reissues: PAR-15-174 Alzheimer's Drug-Development Program (U01)
- 2 steps back: PAR-12-015 Alzheimer's Disease Drug Development Program (U01)
- 3 steps back: PA-10-205 Alzheimers Disease Drug Development Program (U01)
- 4 steps back: PAR-08-266 Alzheimers Disease Drug Development Program (U01)
- 5 steps back: PAR-05-148
Replaced by PAR-18-820.
Who won it before
12 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,371,301 in first-year total cost, median $1,032,315.
Most frequent study sections
- Special Emphasis Panel[ZAG1 ZIJ-6 (M1)]3
- Special Emphasis Panel[ZAG1 ZIJ-6 (O2)]3
- Special Emphasis Panel[ZAG1 ZIJ-6 (J1)]2
- Special Emphasis Panel[ZAG1 ZIJ-6 (J4)]2
- Special Emphasis Panel[ZAG1 ZIJ-6 (J3)]1
Most frequent institutions
- INSTITUTE FOR MOLECULAR MEDICINE2
- UNIVERSITY OF CALIFORNIA, SAN DIEGO2
- ACUMEN PHARMACEUTICALS, INC.1
- EMORY UNIVERSITY1
- OHIO STATE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial1U01AG060965-01 | AGADJANYAN, MICHAEL G | INSTITUTE FOR MOLECULAR MEDICINE, CA | $1,116,260 | ZAG1 |
| 2019 | Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies1U01AG061173-01 | BALLATORE, CARLOBRUNDEN, KURT R. | UNIVERSITY OF PENNSYLVANIA, PA | $948,369 | ZAG1 |
| 2018 | Silent Allosteric Modulation of mGluR5 for Safe and Effective Therapy of Alzheimer's Disease1U01AG058608-01A1 · under PAR-15-174 | STRITTMATTER, STEPHEN M | YALE UNIVERSITY, CT | $1,646,216 | ZAG1 |
| 2018 | Neural Stem Cell Transplantation: A Novel Cellular Therapy for Alzheimer's Disease1U01AG057562-01A1 · under PAR-15-174 | FELDMAN, EVA LUCILLEMURPHY, GEOFFREY G | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $687,010 | ZAG1 |
| 2017 | Development of small molecule activators of glutamate transporter EAAT2 for treatment of Alzheimer's disease1U01AG054444-01A1 · under PAR-15-174 | LIN, CHIEN-LIANG GLENN | OHIO STATE UNIVERSITY, OH | $772,430 | ZAG1 |
| 2017 | Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease1U01AG053247-01A1 · under PAR-15-174 | GOURE, WILLIAM | ACUMEN PHARMACEUTICALS, INC., VA | $444,503 | ZAG1 |
| 2016 | Optimization and preclinical development of soluble gamma-secretase modulators for AD1U01AG048986-01A1 · under PAR-12-015 | WAGNER, STEVEN LEE | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,514,460 | ZAG1 |
| 2016 | Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology1U01AG052460-01A1 · under PAR-15-174 | GANESH, THOTA | EMORY UNIVERSITY, GA | $758,149 | ZAG1 |
| 2015 | Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD1U01AG050636-01 · under PAR-12-015 | VAN ELDIK, LINDA JWATTERSON, DANIEL MARTIN | UNIVERSITY OF KENTUCKY, KY | $1,416,252 | ZAG1 |
| 2015 | Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND1U01AG048310-01A1 · under PAR-12-015 | AGADJANYAN, MICHAEL G | INSTITUTE FOR MOLECULAR MEDICINE, CA | $1,152,198 | ZAG1 |
| 2014 | A Translational Program of BDNF Gene Delivery in Alzheimer's Disease1U01AG043416-01A1 · under PAR-12-015 | TUSZYNSKI, MARK H. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,194,177 | ZAG1 |
| 2014 | Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicolog1U01AG047222-01 · under PAR-12-015 | BRINTON, ROBERTA EILEEN | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $721,277 | ZAG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.